Phase 2RecruitingAge-related condition
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)
- Sponsor
- Emmecell (Industry)
- Enrolment
- 121 planned
- Conditions
- Corneal Edema; Fuchs; Fuchs Dystrophy; Fuchs' Endothelial Dystrophy; Endothelial Corneal Dystrophy; Corneal Endothelial Decompensation; Corneal Endothelial Cell Loss; Corneal Endothelial Disorder; Corneal Endothelial Dystrophy 1; Endothelial Cell Loss, Corneal; Pseudophakic Bullous Keratopathy; Pseudophakic Bullous Keratopathy (PBK)
- Interventions
- 150K cells; 500K cells; Placebo
- Ages
- adults, older adults
- Registry
- NCT07729137
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \[mHCECs\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.
Primary outcomes
- BCVA
History
Study completion expected
Primary completion expected
Started
Last registry update
Registered